Cargando…

Surfactantsubstitutionstherapie: Ein entscheidender Durchbruch in der Behandlung des Atemnotsyndroms Frühgeborener

Surfactant replacement therapy is a major breakthrough in neonatal medicine. Prophylaxis or treatment of neonatal respiratory distress syndrome (RDS) with various surfactant preparations is now a clinical reality. With either strategy the incidence of air leaks and mortality is reduced; more babies...

Descripción completa

Detalles Bibliográficos
Autor principal: Speer, C. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095786/
https://www.ncbi.nlm.nih.gov/pubmed/32226146
http://dx.doi.org/10.1007/s00112-002-0434-y
_version_ 1783510685714481152
author Speer, C. P.
author_facet Speer, C. P.
author_sort Speer, C. P.
collection PubMed
description Surfactant replacement therapy is a major breakthrough in neonatal medicine. Prophylaxis or treatment of neonatal respiratory distress syndrome (RDS) with various surfactant preparations is now a clinical reality. With either strategy the incidence of air leaks and mortality is reduced; more babies with RDS survive without signs of chronic lung disease. The earlier the treatment, the better the outcome. An initial dose of 100 mg/kg can be recommended for all natural preparations, and some babies may benefit from multiple dose treatment. Meta-analyses show a consistent advantage of natural surfactant preparations over the currently available synthetic ones. There is growing evidence that surfactant may also be beneficial in pulmonary diseases of the newborn which are characterized by inactivation of the surfactant system such as meconium aspiration syndrome or neonatal pneumonia.
format Online
Article
Text
id pubmed-7095786
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-70957862020-03-26 Surfactantsubstitutionstherapie: Ein entscheidender Durchbruch in der Behandlung des Atemnotsyndroms Frühgeborener Speer, C. P. Monatsschr Kinderheilkd Neonatologie Surfactant replacement therapy is a major breakthrough in neonatal medicine. Prophylaxis or treatment of neonatal respiratory distress syndrome (RDS) with various surfactant preparations is now a clinical reality. With either strategy the incidence of air leaks and mortality is reduced; more babies with RDS survive without signs of chronic lung disease. The earlier the treatment, the better the outcome. An initial dose of 100 mg/kg can be recommended for all natural preparations, and some babies may benefit from multiple dose treatment. Meta-analyses show a consistent advantage of natural surfactant preparations over the currently available synthetic ones. There is growing evidence that surfactant may also be beneficial in pulmonary diseases of the newborn which are characterized by inactivation of the surfactant system such as meconium aspiration syndrome or neonatal pneumonia. Springer-Verlag 2014-04-24 2002 /pmc/articles/PMC7095786/ /pubmed/32226146 http://dx.doi.org/10.1007/s00112-002-0434-y Text en © Springer-Verlag Berlin Heidelberg 2002 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Neonatologie
Speer, C. P.
Surfactantsubstitutionstherapie: Ein entscheidender Durchbruch in der Behandlung des Atemnotsyndroms Frühgeborener
title Surfactantsubstitutionstherapie: Ein entscheidender Durchbruch in der Behandlung des Atemnotsyndroms Frühgeborener
title_full Surfactantsubstitutionstherapie: Ein entscheidender Durchbruch in der Behandlung des Atemnotsyndroms Frühgeborener
title_fullStr Surfactantsubstitutionstherapie: Ein entscheidender Durchbruch in der Behandlung des Atemnotsyndroms Frühgeborener
title_full_unstemmed Surfactantsubstitutionstherapie: Ein entscheidender Durchbruch in der Behandlung des Atemnotsyndroms Frühgeborener
title_short Surfactantsubstitutionstherapie: Ein entscheidender Durchbruch in der Behandlung des Atemnotsyndroms Frühgeborener
title_sort surfactantsubstitutionstherapie: ein entscheidender durchbruch in der behandlung des atemnotsyndroms frühgeborener
topic Neonatologie
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095786/
https://www.ncbi.nlm.nih.gov/pubmed/32226146
http://dx.doi.org/10.1007/s00112-002-0434-y
work_keys_str_mv AT speercp surfactantsubstitutionstherapieeinentscheidenderdurchbruchinderbehandlungdesatemnotsyndromsfruhgeborener